KER-0193 / Kaerus Bioscience, Servier - LARVOL DELTA

Servier…announced that it has entered into a definitive agreement with Kaerus Bioscience for the acquisition of KER-0193, a potential treatment for Fragile X syndrome (FXS), the most common genetic cause of autism spectrum disorder (ASD) (The Malaysian Reserve) - "Under the terms of the agreement, Kaerus Bioscience will receive an upfront payment for the sale of KER-0193 and will also be eligible for development and commercial earn-out payments. The total value of the deal could reach up to $450M."

Commercial • Autism Spectrum Disorder

Kaerus Bioscience’s lead candidate KER-0193 granted Orphan Drug Designation and Rare Pediatric Drug Designation by U.S. FDA for treatment of Fragile X syndrome (FXS) (PharmiWeb) - "Kaerus Bioscience...announces that its lead candidate KER-0193 has been granted both Orphan Drug Designation and Rare Pediatric Drug Designations for the treatment of Fragile X syndrome (FXS) by the U.S. Food and Drugs Administration (FDA). It follows the recent successful completion of a Phase 1 trial of KER-0193 in healthy volunteers, which confirmed the drug to be safe, well tolerated and exhibit excellent pharmacokinetics."

FDA event • Orphan drug • Fragile X Syndrome